Table 3 UCD cell line oncogenic alterations as determined by oncomine comprehensive assay v3

UCD4

BRCA2

c.1755_1759delGAAAA

p.K585fs*3

P

98%

ESR1

c.1613A>G

D538G

P

100%

FGFR3

Amplification

P

4.63 copies

RAF1

Amplification

LP

4.91 copies

RAD51B

c.246C>G

p.F82L

VUS

47%

FANCD2

Amplification

VUS

4.63 copies

UCD12

BRCA2

c.4943delC

p.A1648fs*22

P

100%

PIK3CA

c.3140A>T

p.H1047L

P

52%

FGFR1

Amplification

P

12.47 copies

RAD51C

Amplification

LP

4.69 copies

FLT3

c.2890G>T

p.E964*

VUS

100%

RNF43

Amplification

VUS

4.83 copies

SLX4

c.2854_2855delGCinsAT

p.A952M

VUS

49%

SPOP

Amplification

VUS

4.1 copies

UCD65

NF1

c.2372dupT

p.L792fs*2

LP

43%

NOTCH2

c.6403_6404delCT

p.L2135fs*2

LP

49%

FGFR1

Amplification

P

13.85 copies

FGF3

Amplification

LP

9.53 copies

FGF19

Amplification

LP

8.24 copies

CCND1

Amplification

P

7.32 copies

GNAS

Amplification

LP

5.19 copies

CREBBP

c.3985C>T

p.L1329L

VUS

50%

UCD46

CCND2

Amplification

P

5.01 copies

PIK3CA

Amplification

P

4.43 copies

TP53

c.281C>G

p.S94*

P

100%

CREBBP

Amplification

LP

4.22 copies

SLX4

Amplification

VUS

4.22 copies

TSC2

Amplification

VUS

4.29 copies

UCD115

TP53

c.892_911dupGAGCTG

CCCCCAGGGAGCAC

p.K305fs*47

P

77%

MYC

Amplification

–

P

6.75 copies

ROS1

Amplification

–

LP

4.36 copies

ERCC2

Amplification

–

LP

4.52 copies

NF1

c.5399_5404del

insCCCAGC

p.V1800_S1802del

insAQP

VUS

49%

PIK3CA

c.1663A>G

p.R555G

VUS

12%

SETD2

c.3224A>T

p.N1075I

VUS

49%

UCD178

MYC

Amplification

P

6.47 copies

MDM2

Amplification

P

5.22 copies

RAF1

amplification

P

4.76 copies

SEC16A-NOTCH1

Fusion

LP

FGFR4

c.826G>A

p.D276N

VUS

46%

NF1

c.3976 T>A

p.L1326I

VUS

100%